Novavax Advances Science Supporting Protein-Based Vaccine Technology At IDWeek 2023 and World Vaccine Congress Europe 2023
Portfolio Pulse from Benzinga Newsdesk
Novavax, Inc. (NASDAQ:NVAX) will present study findings at IDWeek 2023 and World Vaccine Congress Europe 2023. The presentations will include clinical data on Novavax's BA.1, BA.5 and bivalent variant vaccines, an evaluation of its prototype COVID-19 vaccine in children aged 6 to 11 years, real-world evidence on adverse events post-COVID vaccination and an update on its COVID-19-Influenza Combination (CIC) vaccine candidate.
October 11, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax's presentations at upcoming conferences could potentially influence the market's perception of the company's vaccine portfolio, including its COVID-19-Influenza Combination vaccine candidate.
The presentations at the conferences will provide updates on Novavax's vaccine portfolio, including clinical data and real-world evidence. This could potentially influence the market's perception of the company's products, leading to a potential increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100